State Street Corp Graybug Vision, Inc. Transaction History

State Street Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.44 - $6.33 $15,432 - $222,012	-35,073 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$1.74 - $3.6 $25,273 - $52,290	14,525 Added 70.69%	35,073 $64,000
Q3 2021 Nov 15, 2021	SELL	$3.18 - $5.17 $65,587 - $106,631	-20,625 Reduced 50.09%	20,548 $68,000
Q2 2021 Aug 16, 2021	SELL	$3.53 - $6.1 $236,319 - $408,370	-66,946 Reduced 61.92%	41,173 $224,000
Q1 2021 May 17, 2021	BUY	$5.55 - $35.0 $148,185 - $934,500	26,700 Added 32.79%	108,119 $600,000
Q4 2020 Feb 16, 2021	BUY	$13.05 - $33.93 $1.06 Million - $2.76 Million	81,419 New	81,419 $2.36 Million

Ticker GRAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,517,700
Market Cap $63.5M
Description
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the t...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.